Lipid-lowering drugs: Main clinical trials;Hypolipémiants: Bilan des grandes études cardiovasculaires

Therapie

Volumn 58, Issue 1, 2003, Pages 23-29

  Luc, Gérald ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Clinical trials; Coronary heart disease; Lipid lowering drugs

Indexed keywords

ANTILIPEMIC AGENT; COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

AGE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; GENDER; HEART DEATH; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK; SECONDARY PREVENTION;

EID: 0038284767     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003004     Document Type: Article

References (16)

1. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1980; 2: 379-85
2. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
3. Lehtimaki T. Determination of apolipoprotein E phenotypes from stored or postmortero serum samples. Clin Chim Acta 1991; 203: 177-82
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
6. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
9. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33
10. Shepherd J, Cobbe SM, Lorimer AR, et al. Baseline risk factors and their association with outcome in the west of scotland coronary prevention study. Am J Cardiol 1997; 79: 756-62
11. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
12. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8
13. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85: 37-45
14. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998; 352: 1801-7
15. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88: 2762-70
16. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274-5